Quick Answer
Black Diamond Therapeutics, Inc. reported Operating Income Loss of $12.52 million for the year ending 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +115.9% in Operating Income Loss from 2024 to 2025.
- This data is from Black Diamond Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Black Diamond Therapeutics, Inc.'s Operating Income Loss has grown by 240.6%.
- Historical annual values: Fiscal year 2025: $12.52 million | Fiscal year 2024: -$78.78 million | Fiscal year 2023: -$86.46 million | Fiscal year 2022: -$92.83 million | Fiscal year 2021: -$126.87 million | Fiscal year 2020: -$69.57 million | Fiscal year 2019: -$29.33 million | Fiscal year 2018: -$8.90 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: